CAS 170851-70-4 Ipamorelin Powder 99% Purity A Selective Growth Hormone Secretagogue

The development and pharmacology of a new potent growth hormone (GH) secretagogue, ipamorelin, is described. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), which displays high GH releasing potency and efficacy in vitro and in vivo. As an outcome of a major chemistry programme, ipamorelin was identified within a series of compounds lacking the central dipeptide Ala-Trp of growth hormone-releasing peptide (GHRP)-1. In vitro, ipamorelin released GH from primary rat pituitary cells with a potency and efficacy similar to GHRP-6 (ECs) = 1.3+/-0.4nmol/l and Emax = 85+/-5% vs 2.2+/-0.3nmol/l and 100%). A pharmacological profiling using GHRP and growth hormone-releasing hormone (GHRH) antagonists clearly demonstrated that ipamorelin, like GHRP-6, stimulates GH release via a GHRP-like receptor. In pentobarbital anaesthetised rats, ipamorelin released GH with a potency and efficacy comparable to GHRP-6 (ED50 = 80+/-42nmol/kg and Emax = 1545+/-250ng GH/ml vs 115+/-36nmol/kg and 1167+/-120ng GH/ml). In conscious swine, ipamorelin released GH with an ED50 = 2.3+/-0.03 nmol/kg and an Emax = 65+/-0.2 ng GH/ml plasma. Again, this was very similar to GHRP-6 (ED50 = 3.9+/-1.4 nmol/kg and Emax = 74+/-7ng GH/ml plasma). GHRP-2 displayed higher potency but lower efficacy (ED50 = 0.6 nmol/kg and Emax = 56+/-6 ng GH/ml plasma). The specificity for GH release was studied in swine. None of the GH secretagogues tested affected FSH, LH, PRL or TSH plasma levels. Administration of both GHRP-6 and GHRP-2 resulted in increased plasma levels of ACTH and cortisol. Very surprisingly, ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation. This lack of effect on ACTH and cortisol plasma levels was evident even at doses more than 200-fold higher than the ED50 for GH release. In conclusion, ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH. The specificity of ipamorelin makes this compound a very interesting candidate for future clinical development.

• Polypeptide Hormones we supply
  Melanotan II	CAS 121062-08-6	timulate the body's tanning response
  Selank	CAS 129954-34-3	help enhance mental sharpness,enhance memory
  DSIP	CAS 62568-57-4	Delta sleep-inducing peptide, abbreviated DSIP
  Gonadotropin	CAS 71447-49-9	Mainly used for prostate cancer
  Tesamorelin	CAS 218949-48-5	used in the treatment of HIV-associated lipodystrophy
  Triptorelin	CAS 57773-63-4	used as the acetate or pamoate salts
  HG 176-191		the fat-reducing effects
  Pentadecapeptide BPC 157	CAS 137525-51-0	increasing lean muscular tissue mass, reducing fat
  TB500	CAS 77591-33-4	oincrease muscle growth
  Oxytocin	CAS 50-56-6	used for stimulation of uterus contractions
  Sermorelin	CAS 86168-78-7	Increases the development of lean body mass
  Hexarelin	CAS 140703-51-1	the treatment of growth hormone secretion deficiency
  Ipamorelin	CAS 170851-70-4	a selective growth hormone secretagogue
  Melanotan 1	CAS 75921-69-6	endogenous melanocortine peptide
  MGF		used by bodybuilders and athletes
  PEG-MGF		cause site specific muscle growth
  CJC-1295 Without DAC	CAS 863288-34-0	increasing binding affinity to the GHRH receptors
  CJC-1295 with DAC	CAS 863288-34-0	improved physique and sense of well being
  PT-141		increase libido effects of both men and women
  GHRP-2	CAS 158861-67-7	growth hormone stimulation
  GHRP-6	CAS 87616-84-0	Increase in strength,Muscle mass,Body fat loss
  Tb-500	CAS 77591-33-4	increases in endurance,strength and muscle growth